Showing 491-500 of 650 results for "".
- International Women's Day: Botox Cosmetic, IFundWomen Partner for Grant Programhttps://practicaldermatology.com/news/international-womens-day-botox-cosmetic-ifundwomen-for-grant-program/2461596/In honor of International Women's Day, Allergan Aesthetics,’ an AbbVie company, is partnering with IFundWomen, the funding marketplace for women-owned businesses, on a grant program. Women entrepreneurs can apply for the opportunity to receive one of 20 grants worth
- Merz Aesthetics Taps Christina Aguilera as New Xeomin Brand Partnerhttps://practicaldermatology.com/news/merz-aesthetics-taps-christina-aguilera-as-new-xeomin-brand-partner/2461588/Christina Aguilera is the latest Xeomin (incobotulinumtoxinA) brand partner as Merz Aesthetics expands its ‘Beauty on Your Terms’ marketing campaign. Launched in August 2022, the campaign features multiple music icons in support of Xeomin.
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i